| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Iristectorin B targets pathways involved in cancer cell proliferation and ferroptosis. In PC12 cells, it modulates ferroptosis by reducing Ca2+, LDH, and ROS levels. Its anticancer activity in breast cancer involves inhibition of cell proliferation.
|
|---|---|
| ln Vitro |
In vitro, Iristectorin B inhibits the proliferation of breast cancer cells. In PC12 cells, it regulates ferroptosis and reduces oxidative stress markers, suggesting neuroprotective potential.
|
| ln Vivo |
In vivo, Iristectorin B has been studied in stroke models, where it modulates ferroptosis and reduces neuronal damage. Its anticancer activity has also been evaluated in xenograft models of breast cancer.
|
| Enzyme Assay |
Receptor binding assays are not well established for this isoflavone. Studies typically use cell-based assays to evaluate its effects on cell proliferation, ferroptosis, and oxidative stress markers.
|
| Cell Assay |
Breast cancer cell lines (e.g., MCF-7 or MDA-MB-231) or PC12 neuronal cells are cultured and treated with Iristectorin B. Cell proliferation is measured by MTT or CCK-8 assays. Ferroptosis markers such as ROS, LDH, and Ca2+ levels are quantified.
|
| Animal Protocol |
Stroke models in rodents are used to evaluate neuroprotective effects. Iristectorin B is administered orally or intraperitoneally, and parameters such as infarct volume, neurological deficits, and markers of ferroptosis are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Iristectorin B are not extensively characterized. As a glycoside, it is expected to undergo deglycosylation and hepatic metabolism. Bioavailability may be limited.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. Isoflavones are generally considered to have a low toxicity profile. No significant adverse effects have been reported at research doses.
|
| References | |
| Additional Infomation |
According to reports, irises contain irisin B, and relevant data is available for reference.
Iristectorin B is a research compound with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of anticancer and neuroprotective activities. |
| Molecular Formula |
C23H24O12
|
|---|---|
| Molecular Weight |
492.4295
|
| Exact Mass |
492.126
|
| CAS # |
94396-09-5
|
| PubChem CID |
5318487
|
| Appearance |
White to off-white solid powder
|
| Density |
1.582±0.06 g/cm3 (20 ºC 760 Torr)
|
| Boiling Point |
811.7±65.0 °C at 760 mmHg
|
| Flash Point |
280.5±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.676
|
| LogP |
0.05
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
776
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C=CC(=C1)C2=COC3=CC(=C(C(=C3C2=O)O)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
XVNKSNSGLVWSFS-ZTATXHNCSA-N
|
| InChi Code |
InChI=1S/C23H24O12/c1-31-12-5-9(3-4-11(12)25)10-8-33-13-6-14(22(32-2)19(28)16(13)17(10)26)34-23-21(30)20(29)18(27)15(7-24)35-23/h3-6,8,15,18,20-21,23-25,27-30H,7H2,1-2H3/t15-,18-,20+,21-,23-/m1/s1
|
| Chemical Name |
5-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0307 mL | 10.1537 mL | 20.3075 mL | |
| 5 mM | 0.4061 mL | 2.0307 mL | 4.0615 mL | |
| 10 mM | 0.2031 mL | 1.0154 mL | 2.0307 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
